The mechanism of propofol infusion syndrome - the potency of dexmedetomidine as a treatment or prevention of propofol infusion syndrome
| Project/Area Number |
17K17059
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Emergency medicine
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | プロポフォール / プロポフォール注入症候群 / 脂肪製剤 / 脂質過酸化反応 / 骨格筋障害 / 酸化ストレス |
|---|
| Outline of Final Research Achievements |
We used rats and infused 1% propofol and it's solvent, lipofundin for three days. The rats received propofol infusion did not express the symptoms of propofol infusion syndrome, but the rats received lipofundin expressed the elevation of creatine kinase and myoglobin indicating skeletal muscle damage. We detected that lipid peroxidation related the lipid induced skeletal muscle damage. This mechanism was validated by the phenomenon that the alpha-tocopherol, which is one of the vitamin E, suppressed the lipid induced skeletal muscle damage.
We concluded that the lipid which was used as a solvent of propofol induced skeletal muscle damage via lipid peroxidation and propofol itself prevented the skeletal muscle damage by it's anti-oxidative effect. Moreover, we investigated the preventive effect of dexmedetomidine on lipid induced skeletal muscle damage, but dexmedetomidine did not have the attenuating effect of skeletal muscle damage.
|
| Academic Significance and Societal Importance of the Research Achievements |
これまでプロポフォール注入症候群の原因として、プロポフォールによるミトコンドリア機能障害が挙げられていた。しかし、本研究では、プロポフォールの溶媒として使用される脂肪製剤により脂質過酸化反応が生じ、プロポフォール注入症候群の臨床兆候である骨格筋障害を引き起こしていることを明らかにした。つまり、プロポフォール自体だけではなく、溶媒である脂肪製剤にもプロポフォール注入症候群を発生させる原因がある可能性が示唆された。本研究結果によって、プロポフォール注入症候群の病態に関する新たなアプローチが提唱できたことは、病態解析を進める上で、大きな意味を有すると思われる。
|
Report
(4 results)
Research Products
(3 results)
